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Background and Aim: Antiviral therapy has been demonstrated to significantly 
improve the survival in patients with advanced hepatitis B virus (HBV)-related 
hepatocellular carcinoma (HCC). The aim of the study was to investigate the 
cost-effectiveness of antiviral therapy in patients with advanced HBV-related HCC 
treated with sorafenib. 
Methods: To conduct the analysis, a Markov model comprising three health states 
(progression-free survival, progressive disease and death) was created. The efficacy data 
were derived from the medical records. Cost data were collected based on the Chinese 
national drug prices. Utility data came from the previously published studies. One-way 
sensitivity analyses as well as probabilistic sensitivity analyses were performed to 
explore model uncertainties. 
Results: In the base-case analysis, addition of antiviral therapy to sorafenib generated 
an effectiveness of 0.68 QALYs at a cost of $25026.04, while sorafenib monotherapy 
gained an effectiveness of 0.42 QALYs at a cost of $20249.64. The incremental 
cost-effectiveness ratio (ICER) was $18370.77/QALY for antiviral therapy group versus 
non-antiviral therapy group. On the other hand, the ICER between the two groups in 
patients with high or low HBV DNA load, with or without cirrhosis, normal or elevated 
alanine aminotransferase (ALT)/aspartate aminotransferase (AST) were 
$16613.97/QALY, $19774.16/QALY, $14587.66/QALY, $19873.84/QALY, 
$17947.07/QALY and $18785.58/QALY, respectively. 
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Conclusions: Based on the cost-effectiveness threshold ($20301.00/QALY in China), 
addition of antiviral therapy to sorafenib is considered to be a cost-effective option 
compared with sorafenib monotherapy in patients with advanced HBV-related HCC in 
China from the patient’s perspective. 
Keywords: cost-effectiveness, antiviral therapy, hepatitis B virus, hepatocellular 
carcinoma, sorafenib 
Introduction 
Hepatocellular carcinoma (HCC) is the fifth most commonly diagnosed malignancy and 
the second leading cause of cancer death worldwide [1]. Hepatectomy, liver 
transplantation and radiofrequency ablation (RFA) are potentially curative treatments 
for patients with early stage HCC [2]. Unfortunately, most of the HCC patients are 
found incurable at the time of diagnosis due to tumor progression and underlying liver 
dysfunction [3]. Sorafenib has been approved for the treatment of HCC with vascular 
invasion and/or distant metastasis [4, 5]. Regardless of the multiple treatment 
alternatives mentioned above, the clinical outcome of advanced HCC is poor. 
The incidence of HCC in China accounts for more than 50% of cases worldwide and 
chronic HBV infection has been established as the dominant cause [6]. In China, 85% of 
the HCC cases are HBV-related [7]. Some previous studies have revealed a high HBV 
virus load as the key prognostic factor for the progression and recurrence of HCC [8-11]. 
Recently, a series of studies have investigated the function of antiviral therapy in the 
management of HBV-related HCC, which demonstrated that antiviral therapy improved 
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the survival of advanced HBV-related HCC patients when combined with sorafenib, 
especially in patients with high HBV-DNA level [12, 13]. 
However, these studies did not take long-term therapy costs into consideration, which 
might result in a substantial economic burden for advanced HBV-related HCC patients 
due to the antiviral therapy and the prolongation of survival. On the other hand, there 
have been a large number of studies focusing on the cost-effectiveness of antiviral 
treatments in chronic hepatitis B patients, which suggested antiviral therapy is a 
cost-effective option for patients with HBV infection [14-16]. Nevertheless, there has 
been no economic evaluation studying antiviral therapy for advanced HBV-related HCC 
patients treated with sorafenib. Is it a cost-effective strategy to give antiviral therapy 
combined with sorafenib for advanced HBV-related HCC patients? Therefore, the aim 
of the study was to conduct an economic model to evaluate the long-term clinical 
benefit and cost-effectiveness of antiviral therapy for advanced HBV-related HCC 
patients treated with sorafenib. 
Methods 
Patients 
In order to conduct the analysis, the information of a cohort of patients was collected 
from the medical records of the Department of Medical Oncology, Cancer Center, West 
China Hospital, Sichuan University (China): 1. confirmed advanced HCC 
(histologically or clinically confirmed); 2. Eastern Cooperative Oncology Group 
(ECOG) performance status (PS): 0-2; 3. Child-Pugh liver function class A/B; 4. 
This article is protected by copyright. All rights reserved.
4 
 
treatment with sorafenib as first-line regimen from 2010 to 2013; 5. detectable hepatitis 
B surface antigen (HBsAg) positive; 6. without co-infection with other viruses (hepatitis 
A, C, D virus or human immunodeficiency virus (HIV). This retrospective study was 
approved by the Ethics Committee of West China Hospital, Sichuan University. 
Informed consent was obtained from the patients or her/his family members. 
Model structure 
A decision analytic Markov model was constructed to simulate clinical and economic 
outcomes of patients with HBV-related HCC treated with sorafenib. The model 
consisted of three mutually exclusive health states: progression free survival (PFS), 
progressive disease (PD) and death. The cycle length was 1 month and during each 
cycle, the patients either remained in their assigned health state or progressed to another 
health state as represented in Figure 1. Transition probabilities between health states 
were estimated according to the method described by previous studies [17]. 
Cost data 
Potentially differential direct medical costs included the costs of sorafenib, antiviral 
drugs, transcatheter arterial chemoembolization (TACE) and tests (laboratory and 
radiological tests). The prices of sorafenib, antiviral drugs and TACE were obtained 
according to the Chinese national drug prices. The unit costs of laboratory and 
radiological tests were retrieved from West China Hospital, Sichuan University, China. 
Furthermore, the costs of grade 3/4 adverse events (AEs) were also includes in our 
analysis. In addition, we also considered the assistance programs in our study. In the 
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assistance program for sorafenib, the patients paid for the costs of the first 3 months and 
then they got sorafenib for free until the occurrence of endpoints (PD, death, intolerance 
of AEs). All costs were converted to US dollars. 
Effectiveness data 
The effectiveness data of sorafenib group and sorafenib plus antiviral therapy group 
were extracted from the survival analysis of the patients collected from the medical 
records. Health outcomes were denoted in quality-adjusted life years (QALYs) gained 
and utility scores of Markov states were obtained from previously published studies 
[18]. 
Cost-effectiveness analysis 
The cost-effectiveness analysis was conducted from the Chinese patient’s perspective. 
The outcome of the cost-effectiveness analysis was measured as incremental 
cost-effectiveness ratio (ICER) of sorafenib plus antiviral therapy group compared with 
sorafenib monotherapy group, which was calculated as incremental costs divided by 
incremental effectiveness. Willingness to pay (WTP) in the model was set at 3×the per 
capita GDP of China ($20,301.00/QALY) based on the WHO guidelines for 
cost-effectiveness analysis [19]. As the survivals in both groups were short, discount 
rates were not considered in the study. 
Subgroup analyses 
We also conducted subgroup analyses based on several essential clinical variables. The 
efficacy data of patients were also derived from the Kaplan-Meier survival curves of 
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patients in these subgroups. The cost-effectiveness data of addition of antiviral therapy 
to sorafenib compared with sorafenib monotherapy in these subgroups were measured 
as the methods mentioned above. 
Sensitivity analyses 
To examine the impact of parameters uncertainty in our model, one-way sensitivity 
analyses were conducted. The results of the one-way sensitivity analyses were 
expressed as a tornado diagram. Furthermore, a probabilistic sensitivity analysis (PSA) 
based on a Monte-Carlo simulation of 1,000 patients was also conducted, the results of 
which were presented using cost-effectiveness acceptability curves and scatter plots 
diagrams. 
Model creation and data analysis were conducted by TreeAge 2011 (TreeAge, 
Williamstown, Massachusetts, USA) and SPSS Statistics (IBM, Armonk, New York, 
USA). 
Results 
Patients’ clinical characteristics 
Of the total 92 patients fulfilled the inclusion criteria, 41 patients were from the antiviral 
group and 51 were from the non-antiviral group. The data of the patients in both groups, 
including gender, age, hepatitis e antigen (HBeAg), ECOG PS, Child-Pugh 
classification, Barcelona Clinic Liver Cancer (BCLC) stage, alpha fetoprotein (AFP), 
alanine aminotransferase (ALT)/aspartate aminotransferase (AST), total bilirubin 
(TBIL), liver cirrhosis and HBV DNA were analyzed and the results were shown in 
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Table 1. The baseline characteristics were balanced between the two groups and there 
were no significant differences. 
Treatment 
The initial dose of sorafenib for advanced HCC was 400 mg twice per day. In general, 
patients in the antiviral group received 94.2% of the full dosage of sorafenib and 
patients in the non-antiviral group received 90.2% of the full dosage of sorafenib. In the 
antiviral group, 20 patients were treated with lamivudine (LAM, 100 mg per day), 8 
patients were treated with adefovir dipivoxil (ADV, 10 mg per day), 7 patients were 
treated with entecavir (ETV, 0.5 mg per day) and 5 patients were treated with 
telbivudine (LdT, 600 mg per day). Besides, there was one patients treated with adefovir 
dipivoxil (ADV, 10 mg per day) plus entecavir (ETV, 0.5 mg per day). The median 
course of antiviral treatment was 10.3 months (range: 1.7-28 months). During the 
treatment, there were only 2 patients developed viral resistance, one in entecavir group 
and the other in adefovir dipivoxil group. Adefovir dipivoxil (ADV, 10 mg per day) and 
entecavir (ETV, 0.5 mg per day) were added to the patients with entecavir resistance and 
adefovir dipivoxil resistance patients, respectively. Antiviral therapy did not increase 
adverse events to patients treated with sorafenib (Table 2). 
Health outcomes 
The survival data in both groups were presented as Kaplan-Meier survival curves in 
Figure 2. The median overall survival (mOS) was 12.2 months in antiviral group and 
8.0 months in non-antiviral group. In terms of median progression free survival (mPFS), 
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the data was 6.0 months in antiviral group and 4.5 months in non-antiviral group. The 
monthly transition probability between the Markov states and utility scores were 
presented in Table 2. Overall, the effectiveness was 0.68 QALYs in the antiviral group 
and 0.42 QALYs in non-antiviral group. The incremental effectiveness between the two 
groups was 0.26 QALYs. 
Cost 
82.9% (34 of 41) of the patients in the antiviral group and 76.5% (39 of 51) of the 
patients in the non-antiviral group received assistance from the assistance programs. 
The monthly costs of sorafenib, antiviral therapy, TACE, tests and grade 3/4 AEs were 
shown in Table 2. During a life span time, patients in the antiviral group and 
non-antiviral group cost $25026.04 and $20249.64, respectively. The incremental costs 
were $4776.40 between the two groups. 
Cost-effectiveness analysis 
According to the cost analysis and effectiveness analysis described above, the ICER 
between the antiviral group and non-antiviral group was $18370.77/QALY (Table 2). 
Based on the cost-effectiveness threshold that was set in the study, addition of antiviral 
therapy to HBV-related patients treated with sorafenib was of great cost-effectiveness 
value. 
Subgroup analyses 
Furthermore, we conducted a series of subgroup analyses to investigate the 
cost-effectiveness of patients with different essential baseline characteristics (Table 3). 
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Addition of antiviral therapy to sorafenib was suggested as a cost-effective regimen 
both in patients with low (ICER $19774.16/QALY) or high HBV DNA load (ICER 
$16613.97/QALY). Likewise, whether for patients with liver cirrhosis or without liver 
cirrhosis, addition of antiviral therapy to sorafenib was also likely to be a potentially 
cost-effective treatment. We also found similar results in patients with elevated (ICER 
$18785.58/QALY) or normal ALT/AST (ICER $17947.07/QALY). Thus, the subgroup 
analyses demonstrated that addition of antiviral therapy to sorafenib could improve the 
cost-effectiveness of sorafenib monotherapy regardless of above baseline 
characteristics. 
Sensitivity analyses 
To investigate the impact of the most influential variables on our results, one-way 
sensitivity analyses were conducted by varying the model parameters over their range of 
value (±30%). The most influential parameters in both the antiviral group and the 
non-antiviral group were shown in the tornado diagram (Figure 3). In the analyses, the 
key drivers on the results were duration of PFS state for antiviral group, duration of PFS 
state for non-antiviral group and duration of PD state for non-antiviral group. 
Parameters such as utility of PD state, price of sorafenib, costs of tests for antiviral 
group, utility of PFS state, costs of tests for non-antiviral group, costs of TACE for 
non-antiviral group, costs of TACE for antiviral group, costs of antiviral therapy before 
progression, duration of PD state for antiviral group, costs of antiviral therapy after 
progression and extra costs after progression were also important factors influencing our 
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results. However, parameters including costs of AEs for antiviral group and costs of AEs 
for non-antiviral group had little impact on the robustness of the analysis. 
The uncertainty of the cost-effectiveness analysis was also investigated by a 
probabilistic sensitivity analysis. The results of the analysis were presented in Figure 4 
using cost-effectiveness acceptability curves. The acceptability curves showed that 
addition of antiviral therapy to sorafenib was a more cost-effective treatment in 82.2% 
of the simulations at the WTP threshold of $20301.00/QALY. According to WTP 
threshold beyond $20301.00/QALY, combination of antiviral therapy with sorafenib 
was also the better option compared with sorafenib monotherapy. 
Moreover, scatter plots diagrams for our analysis also indicated that addition of antiviral 
therapy to sorafenib was a cost-effective option compared with sorafenib monotherapy 
when the WTP threshold was set at $20301.00/QALY (Figure 4B). 
We also tested the stability of our model from the societal perspective. Overall, patients 
in the antiviral group gained 0.68 QALYs at a cost of $57468.22, while patients in the 
non-antiviral group cost $36233.30 and got 0.42 QALYs. The incremental costs and 
effectiveness between the two groups were $21234.92 and 0.26 QALYs, respectively. 
The ICER between the two groups was $81672.77/QALY. Thus, from the societal 
perspective, addition of antiviral therapy to sorafenib was not demonstrated to be of 
cost-effectiveness value compared with sorafenib monotherapy. 
Discussion 
HCC is rampant in many countries around the world. The incidence of HCC is much 
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higher in China than in any other country [20]. Although a series of treatments have 
improved the overall survival of HCC, the prognosis of advanced HCC is unsatisfactory. 
HBV has been well known as the key risk factor for HCC and a high serum HBV DNA 
load is associated with the progression of HCC in patients with chronic hepatitis B 
[8-11]. Recently, a series of articles suggested that the survival of advanced 
HBV-related HCC was significantly improved by using antiviral therapy [12, 13]. 
However, all these studies are lacking of financial implications [21]. Sorafenib is the 
only molecular agent to treat advanced HCC while it has not been demonstrated to be a 
cost-effective drug in China [22], hence, it is of great importance to distinguish 
population who may benefit from the agent most, or, in other words, to make the agent 
more cost-effective. 
In our study, addition of antiviral therapy to sorafenib improved the effectiveness of 
advanced HBV-related HCC by 0.26 QALYs when compared with sorafenib 
monotherapy (0.68 QALYs vs. 0.42 QALYs) with an incremental cost of $4776.40 
($25026.04 vs. $20249.64). The ICER in our analysis was $18370.77/QALY of 
antiviral group compared with non-antiviral group, which was lower than the WTP 
threshold set in our study ($20301.00/QALY). Thus, based on the results of our study, 
we have demonstrated that addition of antiviral therapy to sorafenib is likely to be a 
cost-effective option for patients with advanced HBV-related HCC in China. 
HBV replication is associated with severe liver cirrhosis and dysfunction and the level 
of serum HBV DNA is an important risk factor for HCC [23]. A high level of HBV 
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DNA in HCC patients independently predicted poor disease-free survival (DFS) and OS 
after surgical resection [8-11]. For HCC patients treated with sorafenib, the impacts of 
the HBV load and antiviral therapy on survival have demonstrated by some 
retrospective studies [12, 13]. Antiviral therapy could improve OS of HBV-related HCC 
patients treated with sorafenib, especially in patients with high baseline HBV DNA load. 
In our study, the efficacy data were consistent with previous studies both in high 
baseline HBV DNA load group and low baseline HBV DNA load group. Addition of 
antiviral therapy to sorafenib was demonstrated to be an economic regimen for patients 
with advanced HBV-related HCC no matter the baseline viral load. The financial 
implication was improved more significantly in the high viral load group as the survival 
was prolonged much longer by antiviral therapy in the high HBV DNA load group than 
in the low HBV DNA load group. It could be interpreted as antiviral therapy could 
decrease HBV DNA replication, decrease the risk of liver failure and increases the 
chances of receiving more treatment modalities for HBV-related HCC. 
A large part of patients with hepatitis B will develop cirrhosis and complications of 
end-stage liver disease [24]. Previous studies have shown the marked decrease in 
survival among patients with decompensated cirrhosis [25, 26]. In our study, we have 
demonstrated that antiviral therapy may decrease the progression of cirrhosis, hepatic 
decompensation and prolong the survival of patients with advanced HBV-related HCC. 
This could be interpreted as antiviral therapy could suppresses HBV replication, 
normalizes liver function, reduces hepatitis necroinflammation and fibrosis in patients 
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with chronic hepatitis B. Thus, addition of antiviral therapy to sorafenib could also 
improve the cost-effectiveness both in liver cirrhosis group and no liver cirrhosis group.  
Liver dysfunction has been also demonstrated as a prognostic factor for HCC, the 
prognosis of unresectable HCC patients with impaired liver function is much worse [27, 
28]. ALT/AST was primary indicators of liver function. Antiviral therapy could 
significantly improve the survival regardless of the ALS/AST status of these patients. 
Moreover, addition of antiviral therapy to sorafenib could improve the economic 
implication of sorafenib both in elevated ALT/AST group and normal ALT/AST group. 
This may be explained as antiviral therapy could decrease the viral load and improve 
liver function in patients with advanced HBV-related HCC [29]. On the other hand, 
given the improved liver function, these patients could become available to more 
treatment option. 
It should be pointed out that cost-effectiveness analysis could be conducted from 
different perspectives, with the argument that which perspective should be used to 
enhance the accuracy and extend the application of the results of the analysis [30]. Thus, 
we also conducted our analysis from the societal perspective in the sensitivity analysis. 
However, the results from the societal perspective were not consistent with the results 
from the patient’s perspective. The ICER was $81672.77/QALY from the societal 
perspective, which was much higher than the cost-effectiveness threshold set in the 
study. Given the high price of sorafenib and the modest incremental effectiveness 
between the two groups, it was no wonder that addition of antiviral therapy to sorafenib 
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was not a more cost-effective option compared with sorafenib monotherapy from the 
societal perspective. 
It is essential that several limitations of this current study need to be addressed. First, as 
the data in our study were retrospectively collected from medical records, prospective 
randomized control trials are required to be further verified the role of antiviral therapy 
in improving the cost-effectiveness of sorafenib in patients with HBV-related HCC. 
Second, due to the lack of utility data for HCC patients in China, the data were obtained 
from literature previously published abroad, which may not reflect the Chinese situation 
exactly. In addition, the costs of the supportive care were not included in our analysis as 
the data were too complicated to calculate. 
In conclusion, our analysis suggested that compared with sorafenib monotherapy, 
addition of antiviral therapy to sorafenib is a more cost-effective option for advanced 
HBV-related HCC patients in China. Moreover, we demonstrated that antiviral therapy 
can also improve the cost-effectiveness of sorafenib regardless of the HBV DNA load, 
with or without cirrhosis and liver function status. To the best of our knowledge, this is 
the first study to investigate the cost-effectiveness of antiviral therapy in patients with 
advanced HBV-related HCC treated with sorafenib. Unlike those clinical trials, this 
analysis provided evidences for addition of antiviral therapy to the treatment of 
HBV-related HCC from an economic aspect and the results of the analysis can also 
make for the decision-making of the patients, the governments and the healthcare 
financial structures. 
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Figure 1 Markov model diagram for advanced hepatitis B virus (HBV) – related 
hepatocellular carcinoma (HCC). 
Figure 2 Kaplan-Meier curves of PFS and OS. 
A. Kaplan-Meier estimates of the progression-free survival of patients in the antiviral 
therapy group and non-antiviral therapy group.  
B. Kaplan-Meier estimates of the overall survival of patients in the antiviral therapy 
group and non-antiviral therapy group. 
Figure 3 Tornado diagram of the one-way sensitivity analysis for ICER. 
ICER, incremental cost-effectiveness ratio; PFS, progression-free survival; PD, 
progressive disease; AEs, adverse events; QALY, quality adjusted life year; TACE, 
transcatheter arterial chemoembolization. 
Figure 4 Cost-effectiveness acceptability curves and scatter plots diagrams of 
antiviral therapy group and non-antiviral therapy group. 
A. Cost-effectiveness acceptability curves of antiviral therapy group and non-antiviral 
therapy group. 
B. Scatter plots diagrams of antiviral therapy group and non-antiviral therapy group. 































Table 1 Baseline characteristics of HBV-related HCC patients treated with sorafenib. 






Median (range) 49 (28-77) 48 (36-77) 50 (28-71) 0.611 
Male [n (%)] 80 (87.0) 36 (87.8) 44(86.3) 0.828 
HBeAg 
Positive [n (%)] 18 (19.6) 9 (22.0) 9 (17.6) 0.605 
Negative [n (%)] 74 (80.4) 32 (78.0) 42 (82.4)  
ECOG PS 
0 [n (%)] 20 (21.7) 8 (19.5) 12 (23.5) 0.894 
1 [n (%)] 63 (68.5) 29 (70.7) 34 (66.7)  
2 [n (%)] 9 (9.8) 4 (9.8) 5 (9.8)  
Child-Pugh class 
A [n (%)] 70 (76.1) 32 (78.0) 38 (74.5) 0.692 
B [n (%)] 22 (23.9) 9 (22.0) 13 (25.5)  
BCLC stage 
B [n (%)] 27 (29.3) 13 (31.7) 14 (27.5) 0.656 
C [n (%)] 65 (70.7) 28 (68.3) 37 (72.5)  
AFP (ng/ml) 
≤ 400 [n (%)] 45 (48.9) 19 (46.3) 26 (51.0) 0.658 
> 400 [n (%)] 47 (51.1) 22 (53.7) 25 (49.0)  
ALT/AST 
Normal [n (%)] 28 (30.4) 12 (29.3) 16 (31.4) 0.827 
Elevated [n (%)] 64 (69.6) 29 (70.7) 35 (68.6)  
TBIL 
Normal [n (%)] 75 (81.5) 31 (75.6) 44 (86.3) 0.190 
Elevated [n (%)] 17 (18.5) 10 (24.4) 7 (13.7)  
Liver cirrhosis 
Yes [n (%)] 43 (46.7) 23 (56.1) 20 (39.2) 0.107 
No [n (%)] 49 (53.3) 18 (43.9) 31 (60.8)  
Pre-sorafenib HBV DNA 
≤104 copies/ml [n (%)] 55 (59.8) 23 (56.1) 32 (62.7) 0.518 
>104 copies/ml [n (%)] 37 (40.2) 18 (43.9) 19 (37.3)  
MVI 
Yes [n (%)] 49 (53.3) 20 (48.8) 29 (56.9) 0.440 
No [n (%)] 43 (46.7) 21 (51.2) 22 (43.1)  
Extrahepatic metastasis 
Yes [n (%)] 23(25.0) 11 (26.8) 12 (23.5) 0.716 
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No [n (%)] 69 (75.0) 30 (73.2) 39 (76.5)  
TACE 
Yes [n (%)] 32 (34.8) 15 (36.6) 17 (33.3) 0.746 
No [n (%)] 60 (65.2) 26 (63.4) 34 (66.7)  
HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HBeAg, hepatitis B e antigen; ECOG PS, Eastern Cooperative Oncology 
Group performance status; BCLC, Barcelona Clinic Liver Cancer; AFP, α-fetoprotein; ALT, alanine aminotransferase; AST, 











































Table 2 Base-case cost and effectiveness estimated. 
 Antiviral group Non-antiviral group 
AEs [n (%)] Total Grade 3/4 Total Grade 3/4 
HFS 21 (51.2) 2 (4.9) 32 (62.7) 4 (7.8) 
Diarrhea 17 (41.5) 3 (7.3) 23 (45.1) 5 (9.8) 
Fatigue 10 (24.4) 0 (0.0) 9 (17.6) 0 (0.0) 
Hypertension 4 (9.8) 0 (0.0) 6 (11.8) 1 (2.0) 
Anorexia 10 (24.4) 2 (4.9) 12 (23.5) 2 (3.9) 
Nausea 9 (22.0) 1 (2.4) 10 (19.6) 2 (3.9) 
Cost per month ($) 
Cost of sorafenib 3643.93 4511.33 
Antiviral cost before PD 123.16 0.00 
Cost of TACE 133.42 195.02 
Cost of tests 182.10 187.06 
AE-related costs 4.51 6.68 
Extra cost after PD 102.50 102.50 
Antiviral cost after PD 58.00 0.00 
  Cost for the PFS state 3953.70 4705.07 
  Costs for the PD state 342.60 289.56 
Utility 
PFS 0.76 0.76 
PD 0.68 0.68 
Death 0 0 
Transition probability 
PPFS-PFS 0.836 0.774 
PPFS-PD 0.109 0.143 
PPFS-death 0.055 0.083 
PPD-PD 0.894 0.820 
PPD-death 0.106 0.180 
Cost ($)   
Cost for the PFS state 22131.08 18466.36 
Cost for the PD state 2148.14 1017.87 
Total cost 25026.04 20249.64 
Incremental cost 4776.40 
Effectiveness (QALYs)   
Effectiveness for the PFS state 0.32 0.22 
Effectiveness for the PD state 0.36 0.20 
Total effectiveness 0.68 0.42 
Incremental effectiveness 0.26 
AEs, adverse events; HFS, hand-foot syndrome; PD, progressive disease; TACE, transcatheter arterial chemoembolization; PFS, 
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progression free survival; QALYs, quality adjusted life years. 
 
 
Table 3 Cost-effectiveness analysis of subgroups classified according to essential parameters. 








Baseline HBV DNA ≤ 
104 copies/mL 
Antiviral 27781.86 4943.54 0.79 0.25 19774.16 
Non-antiviral 22838.32 0.54 
Baseline HBV DNA>104 
copies/mL 
Antiviral 26397.00 6147.17 0.71 0.37 16613.97 
Non-antiviral 20249.83 0.34 
With Liver cirrhosis Antiviral 24584.46 4668.05 0.70 0.32 14587.66 
Non-antiviral 19916.41 0.38 
without liver cirrhosis Antiviral 25872.19 4968.46 0.78 0.25 19873.84 
Non-antiviral 20903.73 0.53 
Elevated ALT/AST Antiviral 26200.60 4508.54 0.68 0.24 18785.58 
Non-antiviral 21692.06 0.44 
Normal ALT/AST Antiviral 25538.12 4845.71 0.76 0.27 17947.07 
Non-antiviral 20692.41 0.49 
QALYs, quality adjusted life years; ICER, incremental cost-effectiveness ratio; HBV, hepatitis B virus; ALT, alanine 
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